Sponsor or institution
Clinical trials and research at Frontera Therapeutics
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Frontera Therapeutics that are recruiting, in China. By phase: Phase 1/2 (3), Early Phase 1 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Gene therapy for diabetic macular edema | Phase 1/2 | Tianjin, Tianjin,China | Recruiting | Jul 9, 2024 |
| Gene therapy for wet age-related macular degeneration | Phase 1/2 | Tianjin, Tianjin,China | Recruiting | Jul 9, 2024 |
| Gene therapy for diabetic macular edema | Phase 1 | Tianjin, Tianjin,China | Recruiting | Jun 23, 2023 |
| Gene therapy for X-linked retinitis pigmentosa | Early Phase 1 | Beijing, Beijing Municipality and 1 other locations | Recruiting | May 24, 2023 |
| Gene therapy for retinal dystrophy caused by RPE65 mutations | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | May 15, 2023 |
All recruiting trials (5)
-
Gene therapy for diabetic macular edema
This study is testing a new gene therapy injection to see if it can improve vision and eye health in people with diabetic macular edema.
-
Gene therapy for wet age-related macular degeneration
This study is testing a new gene therapy to see if it can help people with wet age-related macular degeneration keep their vision and reduce the need for frequent treatments.
-
Gene therapy for diabetic macular edema
This study is testing a new gene therapy to see if it can help people with diabetic macular edema improve their vision and reduce the number of treatments they need.
-
Gene therapy for X-linked retinitis pigmentosa
This study tests a new gene therapy to see if it can help restore vision or slow down the eye disease in boys and men aged 8 to 45 with X-linked retinitis pigmentosa caused by RPGR gene mutations.
-
Gene therapy for retinal dystrophy caused by RPE65 mutations
This study is testing a new gene therapy called FT-001 to see if it can improve vision in people with retinal dystrophy caused by RPE65 mutations.
Quick answers
How many clinical trials run by Frontera Therapeutics are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Early Phase 1: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.